Real-World Data Shows Improved Glucose Control with Invokana

Poor glucose control patients saw significant reductions after 6 months use
Poor glucose control patients saw significant reductions after 6 months use

Once-daily Invokana (canagliflozin; Janssen) was associated with significant improvements in blood glucose control (A1c) in adults with type 2 diabetes even though most patients were already being treated with other antidiabetic agents, including insulin, according to three data analyses. Findings were published in Current Medical Research & Opinion and BMCC Endocrine Disorders.

The retrospective analyses were based on medical and lab data from large administrative claim databases. Patients with type 2 diabetes with an average baseline A1c of 8.5–8.9% who initiated Invokana had an average reduction in A1c of 0.8%–1.1% over a 6 month period. Patients with poor glucose control at baseline (A1c >9%) saw an average reduction of 1.8% after 6 months, with 38% of these patients achieving an A1c of <8%. 

A 6-month analysis (n=4,017) showed that 80% of the patients who used Invokana were receiving other A1c-lowering agents, of which 20% discontinued 1 or more of these treatments after starting Invokana.

Hispanic and Latino Americans had higher baseline A1c levels vs. non-Hispanic and non-Latino Americans. This population group who is at higher risk of developing type 2 diabetes, had average A1c reductions >1% with Invokana use. Further data showed a high proportion of patients obtained A1c and blood pressure goals and a reduction in body weight 3 months after starting Invokana; the proportions generally remained stable until the end of the analysis at 12 months. 

Wing Chow, PharmD, MPH, from Johnson & Johnson stated, "These analyses are consistent with findings from other real-world experience with Invokana, which now includes more than 8 million prescriptions to date, and also provide a valuable addition to the large body of evidence from our clinical trial program."

Invokana, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is indicated with diet and exercise to lower blood glucose in adults with type 2 diabetes. It is available as 100mg and 300mg strength tablets in 30-, 90-, and 500-count bottles as well as 10x10 blister cards.

For more information call (800) 526-7736 or visit Invokana.com.

Loading links....